RIPK2 inhibitors for disease therapy: Current status and perspectives

Tian, Erkang; Zhou, Changhan; Quan, Shuqi; Su, Chongying; Zhang, Guanning; Yu, Quanwei; Li, Juan; Zhang, Jifa

doi:10.1016/j.ejmech.2023.115683

Cited by 3 publications

(1 citation statement)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other recent data support its involvement in antitumor immune responses and immunotherapy resistance ( Song, et al 2022 ). Besides cancer, RIP-2 has also been associated with immune, inflammatory and nervous system diseases, such as systemic lupus erythematosus, allergic asthma, and amyotrophic lateral sclerosis ( Tian, et al 2023 ). These data evidence the role of RIPK2 in processes active in several pathological conditions, including cancer, and its potential as a therapeutic target.…”

Section: Introductionmentioning

confidence: 99%

Expression of Truncated Products at the 5′-Terminal Region of RIPK2 and Evolutive Aspects that Support Their Biological Importance

Villagra,

da Cunha,

Polachini

et al. 2024

Genome Biology and Evolution

View full text Add to dashboard Cite

Alternative splicing is the process of generating different mRNAs from the same primary transcript, which contributes to increase the transcriptome and proteome diversity. Abnormal splicing has been associated with the development of several diseases including cancer. Given that mutations and abnormal levels of the RIPK2 transcript and RIP-2 protein are frequent in tumors, and that RIP-2 modulates immune and inflammatory responses, we investigated alternative splicing events that result in partial deletions of the kinase domain at the N-terminus of RIP-2. We also investigated the structure and expression of the RIPK2 truncated variants and isoforms in different environments. In addition, we searched data throughout Supraprimates evolution that could support the biological importance of RIPK2 alternatively spliced products. We observed that human variants and isoforms were differentially regulated following temperature stress, and that the truncated transcript was more expressed than the long transcript in tumor samples. The inverse was found for the longer protein isoform. The truncated variant was also detected in chimpanzee, gorilla, hare, pika, mouse, rat and tree shrew. The fact that the same variant has been preserved in mammals with divergence times up to 70 million years raises the hypothesis that it may have a functional significance.

show abstract

Section: Introductionmentioning

confidence: 99%

Expression of Truncated Products at the 5′-Terminal Region of RIPK2 and Evolutive Aspects that Support Their Biological Importance

Villagra,

da Cunha,

Polachini

et al. 2024

Genome Biology and Evolution

View full text Add to dashboard Cite

show abstract

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Bai,

Qiao,

et al. 2024

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials

Zhang

Tian

et al. 2023

Cardiovascular Therapeutics

View full text Add to dashboard Cite

Backgrounds. Many clinical trials have demonstrated the value of drug-coated balloons (DCB) for in-stent restenosis. However, their role in de novo lesions is not well documented. The aim of this study is to evaluate the safety and efficacy of the DCB-only strategy compared to other percutaneous coronary intervention strategies for de novo coronary lesions. Methods. The PubMed, Embase, Web of Science, and Cochrane Library Central Register of Controlled Trials (CENTRAL) electronic databases were searched for randomized controlled trials published up to May 6, 2023. The primary outcomes were major adverse cardiac events and late lumen loss. Results. A total of eighteen trials with 3336 participants were included. Compared with drug-eluting stents, the DCB-only strategy was associated with a similar risk of major adverse cardiac events (risk ratio RR = 0.90 ; 95% confidence interval (CI): 0.59 to 1.37, P = 0.631 ) and a significant decrease in late lumen loss (standardized mean difference SMD = − 0.29 , 95% CI: −0.53 to −0.04, P = 0.021 ). This effect was consistent in subgroup analysis regardless of indication, follow-up time, drug-eluting stent type, and dual antiplatelet therapy duration. However, DCBs were inferior to DESs for minimum lumen diameter and percentage diameter stenosis. The DCB-only strategy showed significantly better outcomes for most endpoints compared to plain-old balloon angioplasty or bare metal stents. Conclusions. Interventions with a DCB-only strategy are comparable to those of drug-eluting stents and superior to plain-old balloon angioplasty or bare metal stents for the treatment of selected de novo coronary lesions. Additional evidence is still warranted to confirm the value of DCB before widespread clinical utilization can be recommended.

show abstract

RIPK2 inhibitors for disease therapy: Current status and perspectives

Cited by 3 publications

References 98 publications

Expression of Truncated Products at the 5′-Terminal Region of RIPK2 and Evolutive Aspects that Support Their Biological Importance

Expression of Truncated Products at the 5′-Terminal Region of RIPK2 and Evolutive Aspects that Support Their Biological Importance

RIPK1 inhibitors: A key to unlocking the potential of necroptosis in drug development

Drug-Coated Balloon-Only Strategy for De Novo Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials

Contact Info

Product

Resources

About